Skip to content

Associative Peripheral Stimulation for Reduction of Motor Impairment During Acute Period of Stroke Recovery

Pilot Randomized Controlled Trial Assessing Associative Peripheral Stimulation (APS) for Reduction of Motor Impairment During Acute Period of Stroke Recovery

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06575140
Acronym
APS-PILOT
Enrollment
20
Registered
2024-08-28
Start date
2021-12-18
Completion date
2024-12-31
Last updated
2024-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemiparesis, Hemiparesis;Poststroke/CVA, Stroke, Stroke, Acute, Stroke, Hemorrhagic, Stroke, Ischemic, Stroke Sequelae, Upper Extremity Paresis, Weakness of Extremities as Sequela of Stroke

Keywords

Stroke Rehabilitation, Associative Peripheral Stimulation

Brief summary

Associative Peripheral Stimulation (APS) is a non-invasive therapy intended for stroke rehabilitation involving transcutaneous electrical muscle stimulation paired with voluntary movement. This pilot study investigates whether APS applied during the acute phase of stroke recovery may reduce impairment and improve function in the affected upper extremity.

Interventions

DEVICEAssociative Peripheral Stimulation (APS) 1.0

Associative peripheral stimulation paired with rehabilitative exercises.

DEVICEPeripheral Neuromuscular Stimulation

Random peripheral stimulation paired with rehabilitative exercises.

Sponsors

Ahmed A. Rahim
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

1. Confirmed ischemic or hemorrhagic stroke no earlier than 7 days prior to enrollment; 2. Presentation of hemiparesis or paralysis of the upper extremity due to stroke; 3. Ability to comprehend and follow study instructions; 4. Ability to initiate finger extension (≥3°) at least three times per minute; 5. Fugl-Meyer Assessment (Upper Extremity) score of \<47.

Exclusion criteria

1. Contraindications, intolerance, or high sensitivity to the experimental protocol; 2. History of upper-extremity disability prior to the index stroke; 3. Neurological conditions (other than stroke) affecting motor function; 4. Treatment of spasticity/increased tone in the affected upper extremity (e.g., with Botox injection); 5. Lack of access to a safe and suitable place of discharge for experimental sessions and follow-up visits.

Design outcomes

Primary

MeasureTime frameDescription
Maximum Average of Range of Motion (ROM)5 weeksMeasure of distal extensor function (wrist and fingers). Unit of measurement: degrees (°). Higher scores indicate better outcomes.
Fugl-Meyer Assessment Upper-Extremity (FMA-UE)5 weeksMeasure of motor recovery in stroke patients with hemiparesis. Scoring range: 0 to 66. Higher scores indicate better outcomes.

Secondary

MeasureTime frameDescription
Maximum Average of Range of Motion (ROM)3 monthsMeasure of distal extensor function (wrist and fingers). Unit of measurement: degrees (°). Higher scores indicate better outcomes.
Fugl-Meyer Assessment Upper-Extremity (FMA-UE)3 monthsMeasure of motor recovery in stroke patients with hemiparesis. Scoring range: 0 to 66. Higher scores indicate better outcomes.
Action Research Arm Test (ARAT)5 weeksMeasure of four functional domains: grasp, grip, pinch, and gross arm movement. Scoring Range: 0 to 57. Higher scores indicate better outcomes.

Countries

Mexico

Contacts

Primary ContactAhmed A Rahim, MTM
ahmed.rahim@alumni.ucsf.edu+1 (916) 825-8792

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026